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Serial measurements of GFR in infants using the continuous iothala.
mate infusion technique. We undertook a preliminary study to determine
if a clinical trial was feasible that would compare the effect of a low
protein vs a control formula on GFR and growth in infants with
congenital renal insufficiency (C1,, < 55 mI/mm/I .73 m2). In this report
from the Infant Diet Protein Study, we describe validation of a method
using the plasma clearance of iothalamate (C1,,) as an estimate of
glomerular filtration rate (GFR) and results of the preliminary study
relating to renal function. The plasma C1,, method was validated as an
accurate estimate of GFR by showing it to be the same as the plasma
clearance of inulin (C1,,). In the preliminary study infants who qualified
for the study were randomly assigned to a low protein or control
formula and were followed from 8 to 18 months of age. C1,, was
measured at 8, 14 and 18 months of age in 21 of the infants and at 8 and
18 months of age in all twenty four infants that entered the study.
Average absolute GFR in the 24 infants increased in the 10 month
period from 5.3 2.7 to 7.6 4.5 mi/mm. The percent increase in GFR
was no different in infants whose GFR at 8 months of age was severely
reduced from those whose GFR was only moderately reduced. When
adjusted for age and body size, GFR did not change. Change in mean
C1,, or serum creatinine (Sr) from 8 to 18 months of age between the
infants in each diet groups was not different. We conclude that a clinical
trial enrolling more infants and extending the study period is necessary
to evaluate dietary protein effect.
There is a consensus that most patients with renal disease and
a glomerular filtration rate (GFR) that is less than half normal
will sustain progressive loss of renal function regardless of the
cause [1]. This appears to be true for children with dysplasia,
obstructive uropathy, cortical necrosis, or polycystic kidney
disease, in whom there is no active disease causing further
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injury [2, 3]. These studies show that the rate of progression, as
measured by loss of GFR per year, varies widely from patient to
patient, but that in most patients progressive loss proceeds to
end-stage renal disease.
A similar process is well documented in rats with reduced
renal function secondary to renal ablation or disease. A low
protein diet slows progression of this process in rats [4, 5].
There is evidence from clinical studies suggesting that this may
be true in humans, both adults [6] and children [7, 8], who have
chronic renal insufficiency (CR1). However, no controlled study
in children has been published that tested this hypothesis; the
evidence from a meta-analysis of controlled studies in adults
indicates a benefit [9]. We therefore designed a multicenter
controlled clinical trial to evaluate this question in infants with
CR1. A protocol was developed and a feasibility study was
undertaken.
The first problem to be addressed in testing the effect of a low
protein diet on renal function is how to accurately assess
progression as measured by a change in GFR. Neither serum
creatinine (Sr), its reciprocal [10, 11] nor creatinine clearance
(Car) [12] is sufficiently sensitive for measuring rate of GFR
decline in trials lasting only one to three years. A second
problem, unique to children, is that GFR in normal children is
increasing. The time of greatest increase is during the first two
years of life [13].
We adapted a method for estimating GFR using plasma
steady-state clearance methodology [14], substituted iothala-
mate for inulin as the marker and validated it. We then studied
serial changes in growth and in the C1,, in infants with CR1 (C1,,
< 55 mllmin/1 .73 m2) from 8 to 18 months of age when they
were fed formulas having different levels of protein. We evalu-
ated the change in growth and in GFR during this period of
rapid growth and examined how severity of reduction in GFR at
eight months of age influenced this change. In this report we
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describe validation of the C10 method and changes in serial GFR
in infants who completed the 10 month period of study while
receiving different protein intakes.
Methods
Validation of iothalamate clearance
We compared the plasma C,0 with that of inulin because the
C1, is the reference measure of GFR. Eleven patients and one
volunteer were given loading doses of inulin (40 mg/kg) and
iothalamate meglumine (Conray 60 made by Malinkrodt Medi-
cal Co, St. Louis, Missouri, USA) (2 mg/kg). The loading dose
and sustaining infusion were calculated to attain a serum level
of 0.2 mg/ml for inulin and 0.01 mg/ml for iothalamate. We
estimated the patient's GFR (est GFR) for each clearance study
using the height/S formula [15] (mIlminIl .73 m2) and adjusted
it to the subject's own surface area (SA).
kxHt PtsSA
EstGFR= x
SCr 1.73 m2
In this study we used 0.45 as the constant k throughout. SA
was derived from the standard nomogram or calculated from
the height, weight formula of Haycock and colleagues [16]:
SA = 0.024265 * Wt°5378 * Ht°3964.
A minimum infusion time to reach steady-state serum iothala-
mate (S,,,) was calculated on assumptions that a loading dose
would elevate S, to between 0.6 and 2.4 of steady state and that
the C,0 would be greater than 60% of est GFR. Under these
conditions 2.5 estimated half lives (tV2) would be sufficient to
reach steady state (100 10%) so long as the estimated t'/2,
calculated on 0.6 est GFR, is longer than the true tV2 of the C10.
In 2
Mm infus time (hr) = 2.5 * x —0.6 X est GFR (mI/mm) 60
Blood samples were drawn prior to the loading dose, after the
minimum infusion time, and one hour later.
The C,0 was calculated from the following equation:
infusate lo (mg/ml)
C10 (mi/mm) = x pump speed (ml/min)S.Io (mg/ml)
Feasibility study
The protocol was approved by the Committee on Human
Research for each participating institution. Each guardian
signed a consent form after reading an illustrated brochure
prepared for the study and discussing the protocol with their
physician and research nurse.
Protocol. The feasibility study involved twelve centers. Pa-
tients who met the following criteria entered an adjustment
phase: they were less than six months study age (birth date
adjusted for those who were premature), weighed more than
1500 g at birth, and had a Se,.> 0.5 mg/dl resulting from renal
dysplasia, obstructive uropathy, polycystic disease or perinatal
(2)
cortical necrosis. The adjustment period ran to eight months
study age during which each patient was managed in accor-
dance with a treatment protocol directed to correcting electro-
lyte, acid base and/or mineral imbalances and to assure, insofar
as possible, an adequate energy intake. Patients, during this
period, were fed a formula with an intermediate (8%) protein:
energy (P:E) ratio.' At 8 months study age, if Sr remained
> 0.5 mg/dl, a C,0 study was done. If the C30 was less than 55
mllmin/l.73 m2 they then entered the study phase and were
randomly assigned to receive either a low protein (P:E 5.6%)' or
control (P:E 10.4%)' formula. They were continued on the
assigned formula until they reached 18 months of age when the
study ended. During this period standardized anthropometric,
clinical, and laboratory data were collected every two months
and C,0 studies were repeated at 14 and 18 months.
Average calorie and protein intake were estimated each
month from diet records recorded three days each week every
other week. Calorie intake was recorded as percent normal
relative to Recommended Dietary Allowance (RDA) for height,
and protein intake as g/kg/day. Protein intake also was moni-
(1) tored using the ratio of serum urea nitrogen to serum creatinine
(SUN:Scr).
The clearance protocol used in the feasibility study was as
follows: The loading dose and infusion rate of iothalamate were
calculated as described in the validation study. The est GFR
used in setting up the clearance study was derived from the S
obtained in the individual investigator's institution. Minimum
infusion times, derived from the equation described above,
were set as follows:
4 hr when the est GFR was 2 ml/minlkg body weight
8 hr when the est GFR was between 1 to 2 mllmin/kg
16 hr when the est GFR was between 0.5 to 1.0 ml/min/kg
24 hr when the est GFR was <0.5 mi/mm/kg
A blank (S0), a one hour post-loading dose (S,) and, after the
minimum infusion time, two final blood samples (S2, S3) were
obtained. S2 usually was obtained shortly after the minimal
infusion time, and S3 30 to 60 minutes later. Sometimes S3 was
obtained on the same draw as S2 but was treated separately.
The average of S2 and S3 was used as the steady state S,0. 5,
was used to check on the approximate accuracy of the loading
dose and to compare with S,0; if the ratio of 5, to S,0 fell outside
the limits of 0.6 and 2.4, we declared the study unsatisfactory.
This happened twice owing to dilution errors in making up
either the priming or sustaining infusions.
An untimed urine sample was obtained following the draw for
(3) S2 in 48 studies; iothalamate, creatinine and albumin were
determined on both the steady state serum (2 and S3) and this
urine. From these the true Cr and the fractional clearance of
albumin (0 AIb) were determined.
Analyses of serum, urine and infusate samples for iothala-
mate, creatinine and albumin were performed in the central
(UCSF) laboratory. Samples chilled with frozen gel (4°C) were
shipped express delivery in styrofoam containers to the central
laboratory.
ECFV (ml)
'Formulas were prepared through the courtesy of Ross Laborato-
ries, Columbus, Ohio, USA, and met standards for infant formulas as
set forth in FAO/WHO/UNU technical bulletin 724. = and the Commit-
tee on Nutrition of the American Academy of Pediatrics.
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There was good agreement between the Scr results from the
individual centers and those of the central lab. In only eight
instances was the difference greater than 0.2 mg!dl and in only
two was it greater than 0.3 mgldl. When either occurred, the
analyses were repeated in the central lab, and the average of all
the results from the central lab were entered as central lab Sr.
The central lab Se,. values were used in comparing the calcu-
lated Cr values with those of C50 and in comparing Sr and est
CCr results from patients in the different diet groups.
Laboratory methods. Plasma ultrafiltrate for iothalamate
analysis was prepared with Amicon centrifuge filters. lothala-
mate was determined by HPLC using a reverse phase C18, 5 s
ultrasphere Beckman column and a water; acetonitrile; phos-
phoric acid (990:10:0.5) buffer at pH 2.65; 20 d of plasma
ultrafiltrate were injected onto the column. The peak was read
at 229 A using a Waters UV detector [17]. Retention time was
nine minutes. The B0 or blank values were uniformly low.
Differences between duplicates of 20 samples analyzed blinded
on different runs was less than 2%.
Inulin was measured by the anthrone method [181. Serum and
urine creatinine were measured using Sigma kit 555A. Serum
albumin was measured by the Brom Cresol Green binding
method read at 600 nM. Urine albumin was determined by
nephelometry; it was sensitive to detect albumin concentrations
of 6 mg/liter or greater.
Measured C. The Cr and C10 were compared in 45
clearance studies where (U/P)r and (U/P)10 were both mea-
sured. Cr was calculated by the following equation:
(U/P)r
CCr xC10(U/P)10
Albumin excretion. The excretion rates of albumin were
expressed as 0 Aib and as UAIb/UCr. The 0 albumin was
calculated by the following equation:
[U/P]Alb0 AIb -
[U/P]10
Statistical analysis
To test for trend in GFR measures at study ages 8, 14, and 18
months, univariate repeated measures analysis of variance was
applied to absolute and log-transformed values [19]; orthogonal
linear and quadratic contrasts were tested. For analyses of
these measures with respect to study age, log-transformed
values were used in order to stabilize variability. Tests for
appropriateness of the univariate repeated measures analysis,
that is, of sphericity of the contrasts, and of univariate normal-
ity of log GFR were applied. One-sample t or signed rank tests
were applied to untransformed absolute and relative change
scores. Differences in location between groups were tested
using two-sample t or median tests. In some instances, two-
group analyses of covariance were used with parallel or sepa-
rate slopes on the covariate; equality of slopes and regressions
between groups was tested. Kendall rank correlations were also
tested. The SAS system [20] was used, with linear model
analyses performed by the GLM procedure.
Results
Validation of clearance method
The relation of the C50 to the C5 observed in the validation
study is illustrated in Figure 1. The differences between the C10
and the C11 were not clinically or statistically significant (P 
0.1 by paired t-test and linear regression on both absolute and
log transformed data).
(4) Feasibility study
There were three technical failures in the 72 clearances done
on the 24 patients who completed the study. The C1Jest GFR
using 5Cr data from the respective individual clinical lab was
computed in 67 of the 69 successful studies. In only three
instances was C10 less than 60% of the est GFR. The average
and SD of the ratio of GFR/est GFR was 0.97 0.31; the
(5) coefficient of variation was 28%. Results using central lab Sc1.
data were very similar.
Changes with growth. The averages and distributions of the
absolute GFR (C10), GFR % ni for age and weight, and GFR
adjusted to SA (ml/minll .73 m2) for studies of the 21 children
who had successful clearances measured at 8, 14 and 18 mo are
illustrated in Figure 2 A—C, respectively. Differences between
study ages in means of log-transformed absolute GFR were
highly significant (P = 0.0002), with a significant positive linear
trend (P = 0.004). Thus mean absolute GFR increased signifi-
cantly as the children grew. (For these repeated measures
analyses, tests of sphericity were not significant (P > 0.9), and
in general the assumptions appeared to be quite well satisfied.)
For GFR values, whether expressed as log transformed % nl or
adjusted to 1.73 m2, the differences in means at the different
study ages were not significantly different (% ni, P 0.17;
ml/min/l.73 m2, P = 0.12).
The individual changes in GFR from 8 to 18 months were
examined in more detail using paired clearances that were
available in all 24 children (Table 1). Absolute GFR increased,
both in terms of absolute change (mean increase = 2.3 mllmin;
P 0.0009) and relative change (mean increase = 48%; P
120
100
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cr60
40
20
0
cm
Fig. 1. Comparing C1,, vs. C1,, in 12 subjects, 11 patients and/or
volunteers from the University of California, San Francisco (UCSF),
and] patient from the University of Texas, Houston. The regression of
C1,, on Ci,, is as follows: C1,, = 1.07 + 0.98 * C1,,. The mean and so of
the mean difference is 0.5 1.0; r = 0.99.
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Age
Control
N=13
Low
N=l1 P
GFR 8 5.7 2.6 5.0 2.5 0.50
(C10) 18 8.5 4.6 6.6 4.5 0.28
mi/mm change
8
2.8 2.2
1.2 0.6
1.6 3.6
1.3 0.4
0.34
0.66
S.Cr 18 1.2 0.7 1.6 0.8 0.22
mg/dl change 0 0.3 0.3 0.6 0.15
est GFR 8 6.1 2.6 5.0 2.2 0.29
(Equation 1) 18 9.8 5.2 6.0 2.3 0.039
mi/mm change 3.1 3.1 1.0 1.1 0.012
0.0002). Absolute GFR increased by 20% or more in 15 of the 24
children; it decreased by more than 20% in only one. The
relative increase was as great in those infants whose GFR was
less than 25% nl at eight months of age as it was in those whose
GFR at that age was 25 to 50% nI. The average GFR expressed
either as % ni for age and weight or adjusted to 1.73 m2 body
surface area did not change significantly from 8 to 18 months of
age. Changes in % ni GFR from 8 to 18 months were not
significantly rank correlated with values at eight months (P>
0.4). While change in est GFR (formula of Equation 1) was
statistically significant, errors in transforming the ht/Sr to est
GFR data preclude giving clinical significance to this finding.
Comparing results between study groups
Details of the nutrition and growth data are described in a
separate report [21]. The calorie intake of the two groups each
averaged 92% RDA for height. The average protein intake for
the low and control protein groups, respectively, were, over the
period of study 1.6 0.3 and 2.4 0.4 g/kglday; the average
SUN:Scr ratios were similarly different (low:control diet protein
= 0.67; low:control SUN/SCr = 0.61). Differences between the
diet groups for GFR (C10) and Sr at 8 and 18 months and
changes (18 to 8 months) were examined in the twenty-four
patients using central lab values. The differences were not
significant. The overall change in C10 between the groups from
8 to 18 months also was not significant (Table 1).
C'0
Fig. 3. Comparing calculated C, with C10. The solid line is the line of
identity. Ccr is greater than GFR (C1,). The difference is due to tubular
secretion of creatinine (ts Cr) which varied considerably but averaged
15% of filtered creatinine.
C1,, versus measured Ce,.. When we compared the measured
Cj. calculated from U/P ratios of creatinine and iothalamate
with C10 (Equation 4), the slope was greater than 1.0 (Fig. 3).
The fraction of creatinine that was secreted, (ts Cr), averaged
15 27% (mean si; ts Cr> 0; P < 0.01).
Albumin excretion. The 0 albumin and the urinary albumin
related to urinary creatinine (UAII,/UCr) (Equation 5) were
measured at 8 and 18 months in seven children in the control
group and six children in the low protein group (Table 2).
Microproteinuria did occasionally occur in both groups. The
results, however, were too few to allow meaningful compari-
Sons between the diet groups.
Discussion
The method we developed for measuring the plasma C50,
using an extended constant intravenous infusion of iothalamate
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Table 1. Summary statistics (mean SD) of the differences in
clearances between patients on the control and low protein diet at 8
and 18 months
+
+ Fig. 2. The average and distribution of C1,,
for 21 patients studied at 8, 14 and 18 months
of age. (A) Absolute values which increased
with age, (B) % ni values for age and weight
which remained unchanged, and (C) values
adjusted to 1.73 m2 body surface area which
also remained unchanged. The + is the mean,8 14 18 the middle line is the median, and the other
horizontal lines are the 25 and 75 percentile
Study age lines. The vertical lines describe the range.
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Table 2. Albumin excretion of patients in the control and low groups
O Alb
8 months
0 Alb
18 months
Duff
18—8
Aib/Cra
8 months
Alb/Cr
18 months
Duff
18—8
Pt# X105 mg/mg
c-i
C-2
C-8
C-12
C-l4
C-19
C-23
6
24
5
9
15
7
39
63
33
2
9
14
6
8
57
9
—3
0
—1
—1
—31
0.08
0.73
0.18
0.29
0.36
0.23
2.30
2.10
0.77
0.05
0.26
0.23
0.13
0.38
2.02
0.04
—0.13
—0.03
—0.13
—0.10
—1.92
L-3
L-5
L-7
L-13
L-16
L-17
10
47
96
9
120
16
17
5
14
8
16
5
7
—42
—82
—1
—104
—ii
0.23
0.53
0.22
0.22
3.60
0.34
0.08
0.09
0.03
0.29
0.30
0.11
—0.15
—0.44
—0.19
0.07
—3.30
—0.23
a Mean and range (Barratt:
(0.02—0.03 mg/mg).
Ped Neph p 283) for normal 0.08 mg/mg
to steady state, is a satisfactory alternative to the plasma C1, as
described by Cole et al [14] and to single injection methods. We
describe calculations we used to estimate clearance, infusion
rate, minimum infusion time and whether a steady state had
been reached. In estimating clearance from the ht/Scr formula
(est GFR, Equation 1) for serial studies in this age range we
decided to use the constant 0.45 for each age rather than 0.55
for children past one year of age as is recommended [151.
Tubular secretion of creatinine tends to increase as Cr declines
[121; using the smaller constant empirically adjusts for this
tendency. We decided to use iothalamate because it is easier to
use, less expensive and more consistently available than inulin.
In our experience and the experience of other investigators
[22—24] no clinically significant difference has been noted be-
tween either the renal or plasma C10 and C1. In one report [25]
clearances in a few humans were lowered when probenecid was
given, suggesting that a small fraction of iothalamate was
excreted by tubular secretion. A similar effect of probenecid
upon inulin clearance also was reported, casting some question
on the inference that tubular secretion had occurred. The single
injection method using four or fewer samples has a relatively
high coefficient of variation and is systematically higher be-
cause of the gradient between plasma and interstitial fluid that
persists in single injection clearance studies [26]. Further, the
method is not well suited to infants because it is difficult to get
frequent precisely timed blood samples.
Our protocol when used in the different centers of the
multicenter trial was adhered to with little variation. With
training and experience, research nurses were able to complete
71 of 74 clearance studies satisfactorily; of the 71 there were
two in which the S1 to S10 ratio was outside allowances and a
steady state may not have been reached. 0 Albumin was readily
determined by collecting an untimed urine sample during the
period when S10 was near steady state, and measuring iothala-
mate and albumin on the serum and untimed urine sample. The
method is suitable for estimating GFR where difficulties pre-
clude the measuring of renal clearances. It has advantages over
the single injection method in that its accuracy is greater and
can be verified and fractional clearances of albumin, or other
substances can be simply done.
The protocol resulted in substantial differences in dietary
protein intake between the study groups. These differences
were sufficient to test whether a low versus an average, but not
high, protein intake slowed progression of renal insufficiency.
There were no differences in calorie intake. The lack of signif-
icant difference in change of GFR between the study groups
should not be regarded as evidence that dietary protein differ-
ences in this range have no effect. The small number of patients
in the study and the short period of observation make it
impractical to draw conclusions on that point from this prelim-
inary study. A study using more infants and following each for
a longer period of time is needed to test the hypothesis that
lowering dietary protein to the minimum requirement for nor-
mal children as opposed to the average alters the rate of change
in GFR in infants with reduced renal function. Our findings
indicate that such a study is feasible. Until the question is
resolved, we caution against using very low protein diets.
The findings reaffirm the insensitivity of Sr and CCr, whether
derived from a ht/S. equation or directly measured, as esti-
mates of GFR and encourage the use of more suitable methods.
The finding of microalbuminuria and the relative ease with
which 0AIb can be derived when plasma clearance is measured
by constant infusion suggest this may be another useful indica-
tor for assessing glomerular injury.
The significant findings were the excellent agreement be-
tween the C50 and the C1, and, in the feasibility study, the
increase in absolute GFR (mllmin) that occurred between 8 and
18 months of age. The relative increase was observed as
frequently in those whose reductions in GFR was severe
(< 25% nl) as with those whose reductions in GFR were
moderate (25 to 50% nl). We conclude that the increase in this
period was more a function of developmental stage of the infant
than an indication of the potential for recovery; an increase in
absolute GFR in this age group should be cautiously interpreted
as a sign of recovery. Adjusting GFR to % nl for age and weight
rather than to 1.73 m2 gives a more accurate picture of the
course of GFR in this period of growth when GFR is increasing
at a faster rate than is SA.
Reprint requests to Malcolm A. Holliday, M.D., 12701 Sir Francis
Drake Blvd, Inverness, California 94937-0648, USA.
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